Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Baxter Gains FDA Approval for Sabinanigo Mfg. Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Baxter Gains FDA Approval for Sabinanigo Mfg. Facility

Will continue to supply Sodium Chloride Injection to alleviate drug shortage

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Baxter International Inc. received FDA approval for its supplemental drug application to establish its Sabinanigo, Spain, facility as an approved manufacturing site for 0.9% Sodium Chloride Injection, USP, for the U.S. market.
 
The approval includes product presentations in 250 mL, 500 mL and 1000 mL, which Baxter has been distributing in the U.S. to alleviate a drug shortage with the knowledge of the FDA. These three product presentations of 0.9% Sodium Chloride Injection, USP, known as saline, have been in short supply the past two years.
 
“The approval of an additional manufacturing site for Sodium Chloride Injection in the U.S. gives us greater flexibility to respond to market demand fluctuations and will help as we continue to meet patient and healthcare provider need for this critical product,” said Brik Eyre, president of Baxter’s Hospital Products business. “FDA was quick to recognize the benefit of addressing industry demand for sterile IV solutions in collaboration with companies like Baxter.”
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics